Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospective single-institution study

被引:54
作者
Shaffer, Richard [1 ]
Tyldesley, Scott [1 ]
Rolles, Martin [3 ]
Chia, Stephen [1 ]
Mohamed, Islam [2 ]
机构
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] British Columbia Canc Agcy, Kelowna, BC, Canada
[3] Singleton Hosp, Swansea NHS Trust, Swansea, W Glam, Wales
关键词
Breast cancer; Trastuzumab; Cardiotoxicity; Internal mammary chain irradiation; Radiotherapy; TRIAL COMPARING DOXORUBICIN; BREAST-CANCER PATIENTS; ADJUVANT CHEMOTHERAPY; POSTOPERATIVE RADIOTHERAPY; LOCOREGIONAL FAILURE; TAMOXIFEN; IRRADIATION; MASTECTOMY; PACLITAXEL; DOCETAXEL;
D O I
10.1016/j.radonc.2008.09.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To examine the acute cardiotoxicity of internal mammary chain (IMC) irradiation with concurrent trastuzumab. Materials and Methods: Clinical and cardiac function data were collected on 59 patients with early breast cancer who were treated with adjuvant trastuzumab and chemotherapy with or without radiotherapy (often including IMC) at BC Cancer Agency in 2005. Results: Forty-four of fifty-nine patients received adjuvant radiotherapy (RT). Thirteen had left-sided IMC RT. For left-sided RT, IMC inclusion increased the mean percentage dose to 5% of the heart, but the mean doses to 50% and 90% of the heart were similar. Median baseline left ventricular ejection fraction (LVEF) was 62% and similar in all groups. Median absolute decrease in LVEF after RT was 4%, which was not significantly different according to side or inclusion of IMCs. Trastuzumab was stopped in 11 of 59 patients (18.6%) due to decrease in LVEF After median follow up of 15 months, three patients developed clinical congestive heart failure, none of whom received left-sided IMC RT. Conclusions: There was no excess acute cardiotoxicity observed with the combination of left-sided IMC irradiation and concurrent trastuzumab. (C) 2008 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 90 (2009) 122-126
引用
收藏
页码:122 / 126
页数:5
相关论文
共 18 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Left ventricular ejection fraction and cardiotoxicity: Is our ear really to the ground? [J].
Ewer, Michael S. ;
Lenihan, Daniel J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) :1201-1203
[3]   Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment [J].
Ewer, MS ;
Vooletich, MT ;
Durand, JB ;
Woods, ML ;
Davis, JR ;
Valero, V ;
Lenihan, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7820-7826
[4]   An improved technique for breast cancer irradiation including the locoregional lymph nodes [J].
Hurkmans, CW ;
Saarnak, AE ;
Pieters, BR ;
Borger, JH ;
Bruinvis, IAD .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (05) :1421-1429
[5]   Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J].
Joensuu, H ;
Kellokumpu-Lehtinen, P ;
Bono, P ;
Alanko, T ;
Kataja, V ;
Asola, R ;
Utriainen, T ;
Kokko, R ;
Hemminki, A ;
Tarkkanen, M ;
Turpeenniemi-Hujanen, T ;
Jyrkkiö, S ;
Flander, M ;
Helle, L ;
Ingalsuo, S ;
Johansson, K ;
Jääskeläinen, A ;
Pajunen, M ;
Rauhala, M ;
Kaleva-Kerola, J ;
Salminen, T ;
Leinonen, M ;
Elomaa, I ;
Isola, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :809-820
[6]   TO TREAT OR NOT TO TREAT THE INTERNAL MAMMARY NODES - A POSSIBLE COMPROMISE [J].
MARKS, LB ;
HEBERT, ME ;
BENTEL, G ;
SPENCER, DP ;
SHEROUSE, GW ;
PROSNITZ, LR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (04) :903-909
[7]   Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen:: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial [J].
Overgaard, M ;
Jensen, MB ;
Overgaard, J ;
Hansen, PS ;
Rose, C ;
Andersson, M ;
Kamby, C ;
Kjær, M ;
Gadeberg, CC ;
Rasmussen, BB ;
Blichert-Toft, M ;
Mouridsen, HT .
LANCET, 1999, 353 (9165) :1641-1648
[8]   Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy [J].
Overgaard, M ;
Hansen, PS ;
Overgaard, J ;
Rose, C ;
Andersson, M ;
Bach, F ;
Kjaer, M ;
Gadeberg, CC ;
Mouridsen, HT ;
Jensen, MB ;
Zedeler, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (14) :949-955
[9]   Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group n9831 adjuvant breast cancer trial [J].
Perez, Edith A. ;
Suman, Vera J. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Kaufman, Peter A. ;
Hudis, Clifford A. ;
Martino, Silvana ;
Gralow, Julie R. ;
Dakhil, Shaker R. ;
Ingle, James N. ;
Winer, Eric P. ;
Gelmon, Karen A. ;
Gersh, Bernard J. ;
Jaffe, Allan S. ;
Rodeheffer, Richard J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) :1231-1238
[10]   Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial [J].
Ragaz, J ;
Olivotto, IA ;
Spinelli, JJ ;
Phillips, N ;
Jackson, SM ;
Wilson, KS ;
Knowling, MA ;
Coppin, CML ;
Weir, L ;
Gelmon, K ;
Le, N ;
Durand, R ;
Coldman, AJ ;
Manji, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (02) :116-126